内科学
脂联素
内分泌学
脂肪因子
胰岛素抵抗
医学
脂肪肝
2型糖尿病
生物标志物
2型糖尿病
促炎细胞因子
糖尿病
代谢综合征
肠促胰岛素
疾病
抵抗素
胰岛素
分泌物
瘦素
餐后
代谢紊乱
病例对照研究
作者
Houda Zoubiri,Wassila Saiah,Amel Otmane,Hamza Saidi,Mohamed Makrelouf,Samir Ait Abderrahman,A.E.M. Haddam,Elhadj-Ahmed Koceir
摘要
The triad association among type 2 diabetes mellitus (T2DM), metabolic associated fatty liver disease (MAFLD), and incretin secretion dysfunction, including GLP-1 (glucagon-like peptide-1) secretion dysfunction, maintains a critical cardiovascular risk and liver-related mortality. The aim of this study is to establish interactions between the GLP-1 plasma levels and metabolic syndrome clusters and adipokines profile (leptin, adiponectin, resistin) and proinflammatory cytokines (TNFα, IL-6, IL1β, IL-17) in diabetic subjects with or without MAFLD. The data revealed that insulin resistance (HOMA-IR) is present in all groups. MAFLD is more common in men than in women. The average FLI score in group IV was ≥70, confirming the diagnosis of MAFLD. The disorder of GLP-1 secretion is more pronounced in women than in men. HOMA-IR is negatively associated with plasma GLP-1 depletion in the MAFLD, T2DM, and MAFLD + T2DM groups. Adiponectin levels are decreased in all groups, as for GLP-1. In contrast, leptin, resistin, TNFα, IL-6, IL-1β, and IL-17 levels show an inverse correlation with GLP-1. GLP-1 accurately reflects metabolic and inflammatory status in subjects with MAFLD, T2DM, and diabetes-steatosis. The applied multivariate linear regression model confirms a highly significant association between MAFLD and GLP-1. It appears that plasma GLP-1 can be considered as biomarker in MAFLD and T2DM related to sex-gender disparities. Longitudinal studies are required to confirm these data.
科研通智能强力驱动
Strongly Powered by AbleSci AI